2025-06-09-Jefferies-美国_大盘制药股_邀请与华盛顿政策编辑史蒂夫·乌斯丁就最惠国待遇问题进行网络直播-美国东部时间上午9点_6页_88kb

The content is a Jefferies LLC equity research report on Large Cap Pharma, dated June 9, 2025. It includes an invitation to a live webcast featuring Steve Usdin, discussing potential paths to MFN implementation and industry responses. Analysts involved have provided certifications, expressing independent views on the research. Investment recommendations are categorized as Buy, Hold, or Underperform, with specific return expectations: Buy (15%+), Hold (returns from -10% to +15%), and Underperform (returns at -10% or less). The valuation methodology considers factors like growth, volatility, and expected returns. The report also covers risks, including potential conflicts of interest and market fluctuations, and includes extensive legal disclosures for regulatory compliance across various jurisdictions. Overview details such as analyst credentials and rating distributions are provided.

Key Sections:

• Webcast Invitation: Steve Usdin to discuss MFN on June 9 at 9AM ET.
• Analysts: Team members certify independent views.
• Investment Ratings: Definitions provided for Buy, Hold, Underperform.
• Valuation and Risk: Methodology and warnings on market changes.
• Disclosures: Legal information on conflicts, distribution limits, and regulatory aspects.